alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › cerebrospinal

cerebrospinal

834 studies tagged cerebrospinal, dated 1980-07-01 to 2026-10-16. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Midlife and Late-Life Alzheimer Disease Blood Biomarkers and 11-Year Cognitive Decline 2026-10-16
  2. Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers 2026-10-01
  3. A neurocognitive speech taxonomy for voice biomarkers of Alzheimer's disease 2026-09-25

Studies

834 studies carry this tag.

Date range

1980 to 2026

Top journals

  • Neurology 131
  • Alzheimer s & Dementia 37
  • JAMA neurology 35
  • Alzheimer's research & therapy 28
  • Archives of neurology 25

247 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Nature reviews. Neurology 2020-04-22 Biomarkers

    Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology at the earliest stage of some neurodegenerative disorders, but do not have the scalability needed for population screening.

  2. Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis

    ✓ Peer-reviewed alzhub usefulness score 42 out of 100. Scandinavian journal of clinical and laboratory investigation 2020-04-07 Tau biomarkers

    In the last decades, an important role of cerebrospinal fluid (CSF) biomarkers for Alzheimer disease (AD) diagnosis has emerged.

  3. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. Nature communications 2020-04-03 Caregiving

    Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer's disease (AD), reflecting abnormal tau metabolism in the brain.

  4. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography

    ✓ Peer-reviewed alzhub usefulness score 54 out of 100. JAMA neurology 2020-04-01 Long-term cohort studies

    Fluid and imaging biomarkers of Alzheimer disease (AD) are often used interchangeably, but some biomarkers may reveal earlier stages of disease.

  5. Choroid plexus volume is associated with levels of CSF proteins: relevance for Alzheimer's and Parkinson's disease

    ✓ Peer-reviewed alzhub usefulness score 54 out of 100. Neurobiology of aging 2020-01-16 Mild cognitive impairment

    The choroid plexus (ChP) is a major source of cerebrospinal fluid (CSF) production, with a direct and indirect role in protein clearance, and pathogenesis of Alzheimer's disease (AD).

  6. Glycan biomarkers for Alzheimer disease correlate with T-tau and P-tau in cerebrospinal fluid in subjective cognitive impairment

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The FEBS journal 2020-01-14 Tau biomarkers

    Alzheimer disease (AD) is a devastating disease and a global health problem, and current treatments are only symptomatic.

  7. Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men

    ✓ Peer-reviewed alzhub usefulness score 72 out of 100. Neurology 2020-01-08 Biomarkers

    In response to sleep loss (+17.2%), compared with normal sleep (+1.8%), the evening to morning ratio was increased for t-tau ( p = 0.035).

  8. Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's research & therapy 2020-01-02 Biomarkers

    We conclude that an inverse correlation between levels of inflammation in cortical areas and plasma NfL levels indicates that microglial activation may initially be protective to axons in AD.

  9. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of Alzheimer's disease : JAD 2020-01-01 TREM2 and immune genetics

    There is limited data on cerebrospinal fluid (CSF) biomarkers in sporadic amyloid-β (Aβ) cerebral amyloid angiopathy (CAA).

  10. Consideration of Sex Differences in the Measurement and Interpretation of Alzheimer Disease-Related Biofluid-Based Biomarkers

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. The journal of applied laboratory medicine 2020-01-01 Biomarkers

    The development of cerebrospinal fluid and blood-based biomarkers for Alzheimer disease (AD) and related disorders is rapidly progressing.

  11. Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The journal of applied laboratory medicine 2020-01-01 Down syndrome and Alzheimer's

    Thirty-four years ago, amyloid-β 1-42 peptide was identified in amyloid plaques from brain tissue obtained from patients with Alzheimer disease (AD) and Down syndrome.

  12. Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Alzheimer's disease : JAD 2020-01-01 Biomarkers

    These findings suggest that NfL can be used to monitor cognitive decline in aging and Alzheimer's disease and that an attentional control composite may be a better outcome for tracking general neurodegenerative effects on cognition.

  13. The Association Between Circulating Inflammatory Markers and the Progression of Alzheimer Disease in Norwegian Memory Clinic Patients With Mild Cognitive Impairment or Dementia

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer disease and associated disorders 2020-01-01 Inflammation and the immune system

    Increased levels of inflammatory markers were not associated with faster progression as measured by the annual change on the CDR-SB or MMSE score.

  14. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 65 out of 100. Neurology 2019-12-30 Brain scans and imaging

    These results suggest that WMH primarily affect the risk of progression when CSF measures of neurodegeneration or neuronal injury (as reflected by t-tau) are low.

  15. Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. Scientific reports 2019-12-13 Cognitive tests and assessment

    We evaluated the performance of CSF biomarkers for predicting risk of clinical decline and conversion to dementia in non-demented patients with cognitive symptoms.

  16. Evaluating the reliability of neurocognitive biomarkers of neurodegenerative diseases across countries: A machine learning approach

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. NeuroImage 2019-12-10 Digital health tools

    Accurate early diagnosis of neurodegenerative diseases represents a growing challenge for current clinical practice.

  17. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's & dementia (New York, N. Y.) 2019-12-09 Mild cognitive impairment

    CSF synaptic biomarkers, particularly NPTX2, which regulates synaptic homeostasis, relate to cognition and predict progression in AD beyond Aβ1-42 and Tau.

  18. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's research & therapy 2019-12-05 Tau biomarkers

    Determination of β-amyloid (Aβ) positivity and likelihood of underlying Alzheimer's disease (AD) relies on dichotomous biomarker cut-off values.

  19. Blood biomarkers for memory: toward early detection of risk for Alzheimer disease, pharmacogenomics, and repurposed drugs

    ✓ Peer-reviewed alzhub usefulness score 56 out of 100. Molecular psychiatry 2019-12-02 TREM2 and immune genetics

    Short-term memory dysfunction is a key early feature of Alzheimer's disease (AD).

  20. Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Neurology 2019-11-12 Biomarkers

    The HCTS pattern represents a definable subgroup of non-AD pathophysiology (i.e., T - [N] + ) that is associated with cognitive impairment.

  21. Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. JAMA neurology 2019-11-01 Tau biomarkers

    Blood biomarkers able to diagnose Alzheimer disease (AD) at the preclinical stage would enable trial enrollment when the disease is potentially reversible.

  22. Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Scientific reports 2019-09-27 Tau biomarkers

    Levels of amyloid-β (Aβ) and tau peptides in brain have been associated with Alzheimer disease (AD).

  23. Neuroinflammatory Processes, A1 Astrocyte Activation and Protein Aggregation in the Retina of Alzheimer's Disease Patients, Possible Biomarkers for Early Diagnosis

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Frontiers in neuroscience 2019-09-04 Inflammation and the immune system

    Alzheimer's disease (AD), a primary cause of dementia in the aging population, is characterized by extracellular amyloid-beta peptides aggregation, intracellular deposits of hyperphosphorylated tau, neurodegeneration and glial activation in the brain.

  24. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA neurology 2019-09-01 Biomarkers

    These data support the use of cNfL as a biomarker of neuroaxonal damage and indicate that age-specific and sex-specific (and in some cases disease-specific) reference values may be needed.

  25. [New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood]

    ✓ Peer-reviewed alzhub usefulness score 31 out of 100. Der Nervenarzt 2019-09-01 Tau biomarkers

    In accordance with the current German dementia guidelines, the dementia biomarkers amyloid beta 42, the tau peptides total tau and phosphorylated tau 181 are recommended for cerebrospinal fluid (CSF)-based diagnostics of dementia.

  26. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. JAMA neurology 2019-09-01 Biomarkers

    The mean (SD) age of the 842 participants in cohort 1 was 72 (5.6) years, with a range of 59 to 88 years, and 446 (52.5%) were female.

  27. Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. PloS one 2019-08-20 Tau biomarkers

    Alzheimer's disease (AD) remains a clinical diagnosis but biomarkers from cerebrospinal fluid (CSF) and more lately amyloid imaging with positron emission tomography (PET), are important to support a diagnosis of AD.

  28. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2019-08-01 Biomarkers

    Plasma Aβ42/Aβ40, especially when combined with age and APOE ε4 status, accurately diagnoses brain amyloidosis and can be used to screen cognitively normal individuals for brain amyloidosis.

  29. Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of neuropathology and experimental neurology 2019-08-01 Biomarkers

    Neurofilament light chain (NFL) has been recently introduced as a biomarker of early dementia. 18-Fluorodeoxyglucose positron emission tomography (18F-FDG-PET) is a proxy for regional hypometabolism in Alzheimer disease (AD).

  30. Cerebrospinal Fluid Markers of Synaptic Injury and Functional Connectivity in Alzheimer Disease: Protocol for a Cross-Sectional Study

    ✓ Peer-reviewed alzhub usefulness score 37 out of 100. JMIR research protocols 2019-07-17 Tau biomarkers

    Synaptic loss is the best surrogate for cognitive decline in Alzheimer disease (AD) and is more closely associated with cognitive function than amyloid or tau pathologies.

  31. In vivo Prevalence of Alzheimer Biomarkers in Dementia with Lewy Bodies

    ✓ Peer-reviewed alzhub usefulness score 42 out of 100. Dementia and geriatric cognitive disorders 2019-07-16 Tau biomarkers

    Neuropathological studies indicate concomitant Alzheimer's disease (AD) pathology in patients with dementia with Lewy bodies (DLB).

  32. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA network open 2019-07-03 Tau biomarkers

    Increasing evidence suggests an important role of liver function in the pathophysiology of Alzheimer disease (AD).

  33. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. JAMA neurology 2019-07-01 Biomarkers

    The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia (mean levels: cognitive unimpairment, 32.1 ng/L; mild cognitive impairment, 37.9 ng/L; and AD dementia, 45.9 ng/L; P Conclusions and relevance The findings suggest that plasma NfL can be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and may be useful to monitor effects in trials of disease-modifying drugs.

  34. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development

    ✓ Peer-reviewed alzhub usefulness score 44 out of 100. Expert review of proteomics 2019-06-14 Disparities

    It is not associated with the presence of the APOE -ε4 allele whereas possibly linked to aging, female sex, Hispanic ethnicity and some genetic variants of the chitinase-3-like 1 locus.

  35. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer's disease diagnosis

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of neurology 2019-06-10 Tau biomarkers

    Cerebrospinal fluid (CSF) biomarkers are increasingly used to diagnose Alzheimer's disease (AD).

  36. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia

    ✓ Peer-reviewed alzhub usefulness score 70 out of 100. JAMA 2019-06-01 Biomarkers

    Analyses measured the associations between predictor variables and the memory score, and whether AT(N) biomarker profiles significantly improved prediction of memory z score rates of change beyond a model with clinical and genetic variables only.

  37. CSF Beta-amyloid 1-42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Annals of surgery 2019-06-01 Genetics

    Delirium following surgery is common and associated with adverse outcomes.

  38. Obstructive sleep apnea and longitudinal Alzheimer's disease biomarker changes

    ✓ Peer-reviewed alzhub usefulness score 63 out of 100. Sleep 2019-06-01 Mild cognitive impairment

    Study objectives To determine the effect of self-reported clinical diagnosis of obstructive sleep apnea (OSA) on longitudinal changes in brain amyloid PET and CSF biomarkers (Aβ42, T-tau, and P-tau) in cognitively normal (NL), mild cognitive impairment (MCI), and Alzheimer's disease (AD) elderly.

  39. Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurology 2019-05-08 Biomarkers

    In MCI reverters, abnormal biomarkers for AD pathology are associated with subsequent decline.

  40. Age-related hearing loss accelerates cerebrospinal fluid tau levels and brain atrophy: a longitudinal study

    ✓ Peer-reviewed alzhub usefulness score 54 out of 100. Aging 2019-05-01 Long-term cohort studies

    Age-related hearing loss (ARHL) has been considered as a promising modifiable risk factor for cognitive impairment and dementia.

  41. Inflammatory biomarkers in Alzheimer's disease plasma

    ✓ Peer-reviewed alzhub usefulness score 61 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2019-04-30 Mild cognitive impairment

    Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI.

  42. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's research & therapy 2019-04-22 Getting a diagnosis

    The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ 42 ), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau 181 ) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer's Disease (AD).

  43. The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Molecular psychiatry 2019-03-21 Biomarkers

    In Alzheimer's disease (AD), a single-nucleotide polymorphism in the gene encoding brain-derived neurotrophic factor (BDNF Val66Met ) is associated with worse impact of primary AD pathology (beta-amyloid, Aβ) on neurodegeneration and cognitive decline, rendering BDNF Val66Met an important modulating factor of cognitive impairment in AD.

  44. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2019-03-08 Disease mechanisms

    Axonal degeneration, synaptic dysfunction, astroglial activation, and altered tau metabolism are involved already in preclinical AD.

  45. Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 56 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2019-03-04 Tau biomarkers

    The four emerging CSF biomarkers were significantly elevated in the mutation carriers (n = 235) versus noncarriers (n = 145).

  46. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders

    ✓ Peer-reviewed alzhub usefulness score 68 out of 100. JAMA neurology 2019-03-01 Biomarkers

    Cognitive testing follow-up occurred for 1 to 18 years (mean [SD], 0.98 [2.25] years); autopsy-verified diagnoses were available for 120 of 845 participants with diseases (14.2%).

  47. Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Cellular and molecular life sciences : CMLS 2019-02-15 Disease mechanisms

    Alzheimer's disease (AD) is a multifactorial age-related brain disease.

  48. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Nature Medicine 2019-02 Laboratory science

    This study showed that a simple blood test measuring neurofilament light (NfL), a protein released when brain cells are damaged, can detect the earliest signs of brain degeneration in people carrying genes that cause early-onset familial Alzheimer's disease - years before any symptoms appear.

  49. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Nature medicine 2019-01-21 Biomarkers

    Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for various cerebral proteopathies.

  50. Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer's Disease (AD): A Systematic Review and Meta-Analysis

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. International journal of molecular sciences 2019-01-10 Cognitive tests and assessment

    We performed a meta-analysis to examine the aggregate levels of serum BDNF in patients with AD and individuals with MCI, in comparison with healthy controls.

From across this tag

8 of the 829 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.

All topic tags with their study counts